Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition

Neurochemical Research

Volumn 33, Issue 3, 2008, Pages 430-436

  MacKenzie, Erin M ^a   Grant, Suzanne L ^a   Baker, Glen B ^a   Wood, Paul L ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Northwestern University   (United States)

Author keywords

GABA; Monoamine oxidase; Ornithine; Phenelzine; Phenylethylidinehydrazine; Tranylcypromine

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ORNITHINE; PHENELZINE; TRANYLCYPROMINE;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLITE; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; MALE; MONOAMINE OXIDASE INHIBITORS; ORNITHINE; PHENELZINE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANYLCYPROMINE;

ANIMALIA; RATTUS;

EID: 38949124367     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9448-0     Document Type: Article

References (58)

1. McKenna KF, Baker GB, Coutts RT (1991) N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedeberg's Arch Pharmacol 343:478-482
2. Parent MB, Habib MK, Baker GB (2000) Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine. Biochem Pharmacol 59:1253-1263
3. Caille D, Bergis OE, Fankhauser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, Jarreau FX (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 277:265-277
4. Paslawski T, Treit D, Baker GB, George M, Coutts RT (1996) The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA. Psychopharmacology (Berl) 127:19-24
5. Griebel G, Curet O, Perrault G, Sanger DJ (1998) Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology 37:927-935
6. Sowa BN, Todd KG, Tanay VA, Holt A, Baker GB (2004) Monoamine oxidase inhibitors and development of neuroprotective drugs. Curr Neuropharmacol 2:153-168
7. Wood PL, Khan MA, Moskal JR, Todd KG, Tanay VA, Baker G (2006) Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res 1122:184-190
8. McKim RH, Calverly DG, Dewhurst WG, Baker GB (1983) Regional concentrations of cerebral amines: effects of tranylcypromine and phenelzine. Prog Neuropsychopharmacol Biol Psychiatry 7:783-786
9. Baker GB, LeGatt DF, Coutts RT, Dewhurst WG (1984) Rat brain concentrations of 5-hydroxytryptamine following acute and chronic administration of MAO-inhibiting antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 8:653-656
10. Popov N, Matthies H (1969) Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. J Neurochem 16:899-907
11. Perry TL, Hansen S (1973) Sustained drug-induced elevation of brain GABA in the rat. J Neurochem 21:1167-1175
12. Baker GB, Wong JT, Yeung JM, Coutts RT (1991) Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord 21:207-211
13. McManus DJ, Baker GB, Martin IL, Greenshaw AJ, McKenna KF (1992) Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem Pharmacol 43:2486-2489
14. Paslawski TM, Sloley BD, Baker GB (1995) Effects of the MAO inhibitor phenelzine on glutamine and GABA concentrations in rat brain. Prog Brain Res 106:181-186
15. Todd KG, Baker GB (1995) GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord 35:125-129
16. Parent MB, Habib MK, Baker GB (1999) Task-dependent effects of the antidepressant/antipanic drug phenelzine on memory. Psychopharmacology (Berl) 142:280-288
17. Yang J, Shen J (2005) In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Neuroscience 135:927-937
18. Wong JT, Baker GB, Coutts RT, Dewhurst WG (1990) Long-lasting elevation of alanine in brain produced by the antidepressant phenelzine. Brain Res Bull 25:179-181
19. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB (2001) Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol 21:325-339
20. Parent MB, Master S, Kashlub S, Baker GB (2002) Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochem Pharmacol 63:57-64
21. Michael-Titus AT, Bains S, Jeetle J, Whelpton R (2000) Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 100:681-684
22. Clineschmidt BV, Horita A (1969) The monoamine oxidase catalyzed degradation of phenelzine-l-14C, an irreversible inhibitor of monoamine oxidase-II. Studies in vivo. Biochem Pharmacol 18:1021-1028
23. Clineschmidt BV, Horita A (1969) The monoamine oxidase catalyzed degradation of phenelzine-l-14C, an irreversible inhibitor of monoamine oxidase-I. Studies in vitro. Biochem Pharmacol 18:1011-1020
24. Tipton KF, Spires IP (1972) Oxidation of 2-phenylethylhydrazine by monoamine oxidase. Biochem Pharmacol 21:268-270
25. Yu PH, Tipton KF (1989) Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity. Biochem Pharmacol 38:4245-4251
26. Parent M, Bush D, Rauw G, Master S, Vaccarino F, Baker G (2001) Analysis of amino acids and catecholamines, 5-hydroxytryptamine and their metabolites in brain areas in the rat using in vivo microdialysis. Methods 23:11-20
27. Yu PH, Boulton AA (1991) A comparison of effect of brofaromine, phenelzine and tranylcypromine on the activities of some enzymes involved in the metabolism of different neurotransmitters. Res Commun Chem Pathol Pharmacol 16:141-153
28. Seiler N (2000) Ornithine aminotransferase, a potential target for the treatment of hyperammonemias. Curr Drug Targets 1:119-153
29. Jung MJ, Seiler N (1978) Enzyme-activated irreversible inhibitors of L-ornithine:2-oxoacid aminotransferase. Demonstration of mechanistic features of the inhibition of ornithine aminotransferase by 4-aminohex-5-ynoic acid and gabaculine and correlation with in vivo activity. J Biol Chem 253:7431-7439
30. Jung MJ, Heydt JG, Casara P (1984) Gamma-allenyl GABA, a new inhibitor of 4-aminobutyrate amino transferase. Comparison with other inhibitors of this enzyme. Biochem Pharmacol 33:3717-3720
31. Wong PT, McGeer EG, McGeer PL (1982) Effects of kainic acid injection and cortical lesion on ornithine and aspartate aminotransferases in rat striatum. J Neurosci Res 8:643-650
32. Daune G, Seiler N (1988) Interrelationships between ornithine, glutamate, and GABA. II. Consequences of inhibition of GABA-T and ornithine aminotransferase in brain. Neurochem Res 13:69-75
33. Daune G, Gerhart F, Seiler N (1988) 5-Fluoromethylornithine, an irreversible and specific inhibitor of L-ornithine:2-oxo-acid aminotransferase. Biochem J 253:481-488
34. Seiler N, Daune G, Bolkenius FN, Knodgen B (1989) Ornithine aminotransferase activity, tissue ornithine concentrations and polyamine metabolism. Int J Biochem 21:425-432
35. Yoneda Y, Roberts E, Dietz GW Jr (1982) A new synaptosomal biosynthetic pathway of glutamate and GABA from ornithine and its negative feedback inhibition by GABA. J Neurochem 38:1686-1694
36. Raina A, Pajula RL, Eloranta T (1976) A rapid assay method for spermidine and spermine synthases. Distribution of polyamine-synthesizing enzymes and methionine adenosyltransferase in rat tissues. FEBS Lett 67:252-255
37. Perry TL, Kish SJ, Hansen S, Wright JM, Wall RA, Dunn WL, Bellward GD (1981) Elevation of brain GABA content by chronic low-dosage administration of hydrazine, a metabolite of isoniazid. J Neurochem 37:32-39
38. Matsuyama K, Sendo T, Yamashita C, Sugiyama K, Noda A, Iguchi S (1983) Brain distribution of hydrazine and its GABA elevating effect in rats. J Pharmacobiodyn 6:136-138
39. Tunnicliff G (1989) Inhibitors of brain GABA aminotransferase. Comp Biochem Physiol A 93:247-254
40. Yamada N, Takahashi S, Todd KG, Baker GB, Paetsch PR (1993) Effects of two substituted hydrazine monoamine oxidase (MAO) inhibitors on neurotransmitter amines, gamma-aminobutyric acid, and alanine in rat brain. J Pharm Sci 82:934-937
41. Paslawski T, Iqbal N, Knaus E, Baker GB, Coutts RT (1998) A comparison of the neurochemical effects of acutely administered phenelzine and a putative metabolite. In Proc Ann Meet Canadian College of Neuropsychopharmacology, Montreal
42. Paslawski T, Knaus E, Iqbal N, Coutts RT, Baker G (2001) β-phenylethylidenehydrazine, a novel inhibitor of GABA transaminase. Drug Devel Res 54:35-39
43. Petty F (1995) GABA and mood disorders: a brief review and hypothesis. J Affect Disord 34:275-281
44. Uzunova V, Sampson L, Uzunov DP (2006) Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology (Berl) 186:351-361
45. Zwanzger P, Rupprecht R (2005) Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 30:167-175
46. Tassone DM, Boyce E, Guyer J, Nuzum D (2007) Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 29:26-48
47. Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309
48. Youdim MB, Weinstock M (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech Ageing Dev 123:1081-1086
49. Shuaib A, Kanthan R (1997) Amplification of inhibitory mechanisms in cerebral ischemia: an alternative approach to neuronal protection. Histol Histopathol 12:185-194
50. Green AR, Hainsworth AH, Jackson DM (2000) GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 39:1483-1494
51. Schwartz-Bloom RD, Sah R (2001) gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. J Neurochem 77:353-371
52. Yang Y, Li Q, Miyashita H, Yang T, Shuaib A (2001) Different dynamic patterns of extracellular glutamate release in rat hippocampus after permanent or 30-min transient cerebral ischemia and histological correlation. Neuropathology 21:181-187
53. Wang CX, Shuaib A (2005) NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord 4:143-151
54. Tomitori H, Usui T, Saeki N, Ueda S, Kase H, Nishimura K, Kashiwagi K, Igarashi K (2005) Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke 36:2609-2613
55. Bernstein HG, Muller M (1995) Increased immunostaining for L-ornithine decarboxylase occurs in neocortical neurons of Alzheimer's disease patients. Neurosci Lett 186:123-126
56. Morrison LD, Cao XC, Kish SJ (1998) Ornithine decarboxylase in human brain: influence of aging, regional distribution, and Alzheimer's disease. J Neurochem 71:288-294
57. Zarkovic K (2003) 4-Hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 24:293-303
58. Tanay VA, Todd KG, Baker G (2002) Phenylethylidenehydrazine, a novel GABA-T inhibitor rescues neurons after cerebral ischemia. Int J Neuropsychopharmacol 5:S94